Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ASH 2019 | Oral time-limited duvelisib/venetoclax in R/R CLL

Matthew Davids • 7 Dec 2019
ASH 2019
Chronic Lymphocytic Leukemia Leukemia Duvelisib Venetoclax

Matthew Davids, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the phase I trial (NCT03534323) assessing duvelisib in combination with venetoclax as a possible treatment for patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL). Early efficacy data for this 1-year time-limited, all oral regimen are promising. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

More from Matthew Davids

Targeted therapies that appear likely to impact CLL practice in the coming years
1:51
Targeted therapies that appear likely to impact CLL practice in the coming years
Matthew Davids • 8 Dec 2025
Developing and testing a tandem CD19/ROR1 CAR-NK to overcome apoptotic resistance in CLL
1:21
Developing and testing a tandem CD19/ROR1 CAR-NK to overcome apoptotic resistance in CLL
Matthew Davids • 8 Dec 2025
Fixed-duration and MRD-adapted therapy in CLL: insights from ASH 2025
2:08
Fixed-duration and MRD-adapted therapy in CLL: insights from ASH 2025
Matthew Davids • 8 Dec 2025
Mutation-guided finite-duration AV after first-line BTKi+ven-based therapy in CLL/SLL: MAVRiC trial
1:27
Mutation-guided finite-duration AV after first-line BTKi+ven-based therapy in CLL/SLL: MAVRiC trial
Matthew Davids • 8 Dec 2025

Related Videos

cAMeLot-2: Phase III trial of bleximenib + venetoclax + azacitidine in AML with KMT2A/NPM1 mutations
1:10
cAMeLot-2: Phase III trial of bleximenib + venetoclax + azacitidine in AML with KMT2A/NPM1 mutations
Matthew Davids • 24 Nov 2025
Single-agent SC blinatumomab in R/R B-ALL: Phase I/II efficacy results with extended follow-up
1:16
Single-agent SC blinatumomab in R/R B-ALL: Phase I/II efficacy results with extended follow-up
Matthew Davids • 24 Nov 2025
The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
2:53
The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
Matthew Davids • 6 Dec 2025
Bexobrutideg in CLL and approaching the sequencing of BTK degraders and inhibitors
2:20
Bexobrutideg in CLL and approaching the sequencing of BTK degraders and inhibitors
Matthew Davids • 6 Dec 2025
The content of VJHemOnc is intended for healthcare professionals